1. 143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). (23rd October 2018) Authors: Martin-Liberal, J; Pagliuca, F; Hierro, C; Viaplana, C; Muñoz Couselo, E; Capdevila, J; Matos, I; Fariñas Madrid, L; Zamora, E; Braña Garcia, I; Elez Fernandez, E; Ochoa De Olza Amat, M; Azaro, A; Alsina, M; Vieito Villar, M; Fasani, R; Tabernero, J; Garralda, E; Dienstmann, R; Nuciforo, P G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 988PBenefit from subsequent conventional cytotoxic chemotherapy (CTx) to immunotherapy (IT) in patients (pts) with gynaecological malignancies (GM). (23rd October 2018) Authors: Ros Montañá, F J; Rodriguez Freixinos, V; Fariñas Madrid, L; Amair Pinedo, F; Ruiz-Pace, F; Garralda, E; Dienstmann, R; Oaknin, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗